LETTER
Can Ivermectin be Useful for COVID-19 Management as an Immunomodulating Agent?
Sergey Sheleg1, *
iD
Article Information
Identifiers and Pagination:
Year: 2020Volume: 12
First Page: 7
Last Page: 8
Publisher Id: TOIDJ-12-7
DOI: 10.2174/1874279302012010007
Article History:
Received Date: 17/8/2020Revision Received Date: 11/11/2020
Acceptance Date: 13/11/2020
Electronic publication date: 31/12/2020
Collection year: 2020
© 2020 Sergey Sheleg.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The possibility of using ivermectin in the treatment of COVID-19 as an immunomodulating agent, has been discussed, which may prevent life-threatening virally driven cytokine storm syndrome.
Keywords: COVID-19, Ivermectin, NF-kB, Cytokine, Cytokine storm syndrome, Immunomodulator.
